Zhao HQ, Dong BL, Zhang M, Dong XH, He Y, Chen SY, Wu B, Yang XJ. Increased KIF21B expression is a potential prognostic biomarker in hepatocellular carcinoma. World J Gastrointest Oncol 2020; 12(3): 276-288 [PMID: 32206178 DOI: 10.4251/wjgo.v12.i3.276]
Corresponding Author of This Article
Xiao-Jun Yang, MD, PhD, Chief Doctor, Professor, Department of General Surgery, Gansu Provincial Hospital, No. 204, Donggang West Road, Lanzhou 730000, Gansu Province, China. yangxjmd@aliyun.com
Research Domain of This Article
Oncology
Article-Type of This Article
Basic Study
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
World J Gastrointest Oncol. Mar 15, 2020; 12(3): 276-288 Published online Mar 15, 2020. doi: 10.4251/wjgo.v12.i3.276
Increased KIF21B expression is a potential prognostic biomarker in hepatocellular carcinoma
Hui-Qi Zhao, Bao-Long Dong, Min Zhang, Xiao-Hua Dong, Yu He, Shi-Yong Chen, Biao Wu, Xiao-Jun Yang
Hui-Qi Zhao, Bao-Long Dong, Xiao-Hua Dong, Xiao-Jun Yang, Department of General Surgery, Gansu Provincial Hospital, Lanzhou 730000, Gansu Province, China
Min Zhang, Department of Pathology, Gansu Provincial Hospital, Lanzhou 730000, Gansu Province, China
Yu He, School of Clinical Medicine, Gansu University of Chinese Medicine, Lanzhou 730000, Gansu Province, China
Shi-Yong Chen, Biao Wu, School of Clinical Medicine, Ningxia Medical University, Yinchuan 750000, Gansu Province, China
Author contributions: Zhao HQ, Dong BL, and Zhang M contributed equally to this work and should be considered as co-first authors. All authors substantially contributed to the conception and design of the study as well as acquisition, analysis, and interpretation of data; all authors drafted the article and made critical revisions related to the intellectual content of the manuscript, and approved the final version of the article to be published.
Supported bythe National Natural Science Foundation of China, No. 81260326 and No. 81660398; the Natural Science Foundation of Gansu Province, No. 17JR5RA034.
Institutional review board statement: This study was reviewed and approved by the Ethics Committee of the Gansu Provincial hospital (2019-063).
Conflict-of-interest statement: All authors declare no conflicts of interest related to this article.
Data sharing statement: No additional data are available.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Corresponding author: Xiao-Jun Yang, MD, PhD, Chief Doctor, Professor, Department of General Surgery, Gansu Provincial Hospital, No. 204, Donggang West Road, Lanzhou 730000, Gansu Province, China. yangxjmd@aliyun.com
Received: October 23, 2019 Peer-review started: October 23, 2019 First decision: November 18, 2019 Revised: November 24, 2019 Accepted: December 23, 2019 Article in press: December 23, 2019 Published online: March 15, 2020 Processing time: 136 Days and 6.2 Hours
ARTICLE HIGHLIGHTS
Research background
As one of the most frequent cancers, the morbidity and mortality of hepatocellular carcinoma (HCC) is increasing year by year. The kinesin superfamily protein member KIF21B plays an important role in regulating mitotic progression; however, the function and mechanisms of KIF21B in cancer, particularly in HCC, are unknown.
Research motivation
To explore the role of KIF21B in hepatocellular carcinoma and its clinical significance.
Research objectives
The study aimed to investigate the function of KIF21B in HCC and its effect on prognosis after hepatectomy.
Research methods
First, we analyzed the differential expression of KIF21B in The Cancer Genome Atlas, and used immunohistochemical staining to validate it. Subsequently, after silencing KIF21B expression, the function of KIF21B in HCC lines was investigated by cell growth assay, MTT assay, fluorescence-activated cell sorting assay, and colony formation assay. The Kaplan-Meier method was used to assess its prognostic significance.
Research results
KIF21B expression levels were significantly higher in HCC tissues. Functional experiments showed that KIF21B knockdown remarkably suppressed cell proliferation and induced apoptosis. Statistical analyses revealed KIF21B as an independent risk factor in patients with HCC after hepatectomy.
Research conclusion
KIF21B plays an important role in HCC progression and may be a potential diagnostic and prognostic marker for HCC.
Research perspective
In the future, more studies are needed to determine the effect that KIF21B may have on other tumor cell lines and to investigate the underlying mechanism.
